logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2020 — Towards a new combination therapy as first-line treatment in advanced renal cell carcinoma

Combining nivolumab and cabozantinib leads to better survival outcomes compared to sunitinib in treatment-naïve patients with clear cell disease.